Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 4/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799744 | 0.84 | TLR7 (0.40) | GRM5FPR1FPR2AKT1KDM4E | |
| SCHEMBL17799641 | 0.82 | GRM5 (0.51) | GRM5FPR1FPR2AKT1KDM4E | |
| SCHEMBL17799721 | 0.82 | HCRTR1 (0.47) | FPR1FPR2AKT1TLR7 | |
| SCHEMBL17799694 | 0.82 | P2RX7 (0.47) | FPR1FPR2AKT1KDM4ESSTR4 | |
| SCHEMBL16372224 | 0.82 | GRM5 (0.51) | GRM5FPR1FPR2AKT1KDM4E | |
| SCHEMBL16371875 | 0.82 | P2RX7 (0.47) | FPR1FPR2AKT1KDM4ESSTR4 | |
| SCHEMBL17799683 | 0.82 | GRM5 (0.50) | GRM5 | |
| SCHEMBL17799629 | 0.80 | HCRTR1 (0.52) | FPR1AKT1SSTR4 | |
| SCHEMBL16371914 | 0.79 | AKT1 (0.40) | FPR1FPR2AKT1 | |
| SCHEMBL17799665 | 0.79 | AKT1 (0.40) | FPR1FPR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | GRM5 550/4885FPR1 605/4885FPR2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.